{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:27:37Z","timestamp":1786987657628,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.det.2024.12.014","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:51:50Z","timestamp":1737445910000},"page":"317-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hidradenitis Suppurativa in Children"],"prefix":"10.1016","volume":"43","author":[{"given":"Raveena","family":"Ghanshani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Aleshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/pde.15574","article-title":"Pediatric hidradenitis suppurativa publication trends: 2012 to 2022","volume":"41","author":"Park","year":"2024","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.12.014_bib2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jid.2018.04.001","article-title":"Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis","volume":"138","author":"Garg","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib3","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-061049","article-title":"Hidradenitis suppurativa in pediatric patients","volume":"151","author":"Cotton","year":"2023","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000493465","article-title":"Adolescent-onset hidradenitis suppurativa: prevalence, risk factors and disease features","volume":"235","author":"Molina-Leyva","year":"2019","journal-title":"Dermatology"},{"issue":"9","key":"10.1016\/j.det.2024.12.014_bib5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamadermatol.2021.2865","article-title":"Differences between children and adults with hidradenitis suppurativa","volume":"157","author":"Hallock","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/pde.14765","article-title":"Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: a retrospective analysis","volume":"38","author":"Seivright","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib7","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations","volume":"86","author":"Garg","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaad.2020.05.090","article-title":"New-onset depression among children, adolescents, and adults with hidradenitis suppurativa","volume":"83","author":"Wright","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaad.2021.06.843","article-title":"Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa","volume":"86","author":"Wright","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2020.09.072","article-title":"Quality of life in hidradenitis suppurativa: a cross-sectional study of a pediatric population","volume":"84","author":"McAndrew","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.12.014_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jdin.2023.05.011","article-title":"Characteristics and treatment pathways in pediatric and adult hidradenitis suppurativa: an examination using real world data","volume":"12","author":"Hardin","year":"2023","journal-title":"JAAD Int"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","article-title":"Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa","volume":"35","author":"Boer","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jemermed.2011.05.035","article-title":"The use of cephalosporins in penicillin-allergic patients: a literature review","volume":"42","author":"Campagna","year":"2012","journal-title":"J\u00a0Emerg Med"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09546634.2019.1670779","article-title":"Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study","volume":"32","author":"Patel","year":"2021","journal-title":"J\u00a0Dermatol Treat"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib15","article-title":"Monitoring vitamin B","volume":"11","author":"Mastroianni","year":"2019","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib16","doi-asserted-by":"crossref","first-page":"101103","DOI":"10.1016\/j.disamonth.2020.101103","article-title":"Acne in the first three decades of life: an update of a disorder with profound implications for all decades of life","volume":"67","author":"Greydanus","year":"2021","journal-title":"Dis Mon"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000100883","article-title":"Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study","volume":"214","author":"Brocard","year":"2007","journal-title":"Dermatology"},{"issue":"0 1","key":"10.1016\/j.det.2024.12.014_bib18","first-page":"S1","volume":"21 Suppl 1","author":"Mechanick","year":"2013","journal-title":"Obesity"},{"issue":"10","key":"10.1016\/j.det.2024.12.014_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00403-020-02053-6","article-title":"Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients","volume":"312","author":"Riis","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.jaad.2017.07.008","article-title":"Topical 15% resorcinol for hidradenitis suppurativa: an uncontrolled prospective trial with clinical and ultrasonographic follow-up","volume":"77","author":"Pascual","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000536094","article-title":"Expert practices in hidradenitis suppurativa flare management: a cross-sectional survey study","volume":"10","author":"Masson","year":"2024","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib23","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-061350","article-title":"Antibiotic exposure and dental health: a systematic review","volume":"152","author":"Ravindra","year":"2023","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.det.2024.12.014_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0009922806290026","article-title":"Absence of tooth staining with doxycycline treatment in young children","volume":"46","author":"Volovitz","year":"2007","journal-title":"Clin Pediatr (Phila)"},{"issue":"11","key":"10.1016\/j.det.2024.12.014_bib25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/1060028019863796","article-title":"Doxycycline and tooth discoloration in children: changing of recommendations based on evidence of safety","volume":"53","author":"Stultz","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjd.19867","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa in patients of paediatric age: a pilot prospective study","volume":"185","author":"Bettoli","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.014_bib27","doi-asserted-by":"crossref","first-page":"106885","DOI":"10.1016\/j.ijantimicag.2023.106885","article-title":"Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infections","volume":"62","author":"Goulenok","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/bjd\/ljac120","article-title":"Dapsone therapy for hidradenitis suppurativa: a retrospective review of characteristics and treatment outcomes in a cohort of 122 patients in a tertiary dermatology setting","volume":"188","author":"Steyn","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib29","doi-asserted-by":"crossref","first-page":"e15161","DOI":"10.1111\/dth.15161","article-title":"Dapsone in hidradenitis suppurativa: a case series of 56 patients","volume":"34","author":"L\u00f3pez-Llunell","year":"2021","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamadermatol.2023.6201","article-title":"Efficacy and durability of intravenous ertapenem therapy for recalcitrant hidradenitis suppurativa","volume":"160","author":"Nosrati","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.12.014_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2023.04.025","article-title":"Trimethoprim\/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: a series of 16 cases","volume":"37","author":"Masson","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib32","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/JW9.0000000000000162","article-title":"Prednisone and amoxicillin\/clavulanic acid for the treatment of hidradenitis suppurativa flares: a prospective observational study","volume":"10","author":"Gibson","year":"2024","journal-title":"Int J Womens Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.12.014_bib33","first-page":"1231","article-title":"Metformin as adjunctive therapy for pediatric patients with hidradenitis suppurativa","volume":"19","author":"Moussa","year":"2020","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.12.014_bib34","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","article-title":"Metformin for the treatment of hidradenitis suppurativa: a little help along the way","volume":"27","author":"Verdolini","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.25.1.89","article-title":"Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial","volume":"25","author":"Jones","year":"2002","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A\u00a0case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/pde.14391","article-title":"Use of spironolactone to treat acne in adolescent females","volume":"38","author":"Roberts","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaad.2020.11.044","article-title":"Spironolactone in the treatment of adolescent acne: a retrospective review","volume":"85","author":"Berman","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.12.014_bib39","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/adc.56.12.934","article-title":"Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease","volume":"56","author":"Hobbins","year":"1981","journal-title":"Arch Dis Child"},{"issue":"5 Pt 1","key":"10.1016\/j.det.2024.12.014_bib40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0022-3476(05)81373-3","article-title":"Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia","volume":"124","author":"Kao","year":"1994","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.det.2024.12.014_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/09546630510031403","article-title":"Hidradenitis suppurativa treated with finasteride","volume":"16","author":"Joseph","year":"2005","journal-title":"J\u00a0Dermatol Treat"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib42","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamadermatol.2013.2874","article-title":"Finasteride for the treatment of hidradenitis suppurativa in children and adolescents","volume":"149","author":"Randhawa","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/pde.13216","article-title":"Hidradenitis suppurativa in children treated with finasteride-A case series","volume":"34","author":"Mota","year":"2017","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0010-7824(90)90039-X","article-title":"Progestational and androgenic receptor binding affinities and in\u00a0vivo activities of norgestimate and other progestins","volume":"41","author":"Phillips","year":"1990","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.det.2024.12.014_bib45","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/TCRM.S6864","article-title":"Use of ethinylestradiol\/drospirenone combination in patients with the polycystic ovary syndrome","volume":"4","author":"Mathur","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/11532910-000000000-00000","article-title":"Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study","volume":"30","author":"Anthuber","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0002-9378(88)90766-1","article-title":"Hidradenitis suppurativa of the anogenital region: response to isotretinoin","volume":"158","author":"Brown","year":"1988","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib48","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/0378-6323.152741","article-title":"Prepubertal onset of hidradenitis suppurativa in a girl: a case report and literature review","volume":"81","author":"Stojkovic-Filipovic","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0190-9622(84)70199-X","article-title":"Evaluation of isotretinoin treatment of hidradenitis suppurativa","volume":"11","author":"Dicken","year":"1984","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2230.1986.tb00512.x","article-title":"Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin","volume":"11","author":"Norris","year":"1986","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib51","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40257-022-00725-9","article-title":"Drug survival of oral retinoids in hidradenitis suppurativa: a real-life cohort study","volume":"23","author":"Bouwman","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.014_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjd.12104","article-title":"Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review","volume":"168","author":"Blok","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib53","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1111\/ijd.14789","article-title":"Polyclonal gammopathy in an adolescent affected by Dent disease 2 and hidradenitis suppurativa","volume":"59","author":"Marzuillo","year":"2020","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaad.2020.02.071","article-title":"Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: a series of 12 cases","volume":"83","author":"Fougerousse","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.12.014_bib55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpeds.2018.05.042","article-title":"Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn's disease","volume":"201","author":"Horneff","year":"2018","journal-title":"J\u00a0Pediatr"},{"issue":"10378","key":"10.1016\/j.det.2024.12.014_bib56","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.det.2024.12.014_bib57","unstructured":"A multicenter, open-label, randomized study to assess the pharmacokinetics, safety, and efficacy of two doses of bimekizumab in adolescent study participants with moderate to severe plaque psoriasis. National library of medicine (US), Available at: https:\/\/clinicaltrials.gov\/study\/NCT04718896 (Accessed 1 August 2024)."},{"issue":"10443","key":"10.1016\/j.det.2024.12.014_bib58","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib59","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/pde.13775","article-title":"Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa","volume":"36","author":"Provini","year":"2019","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib60","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjd.21066","article-title":"High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa","volume":"187","author":"Jiang","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.014_bib64","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/09546634.2015.1094179","article-title":"Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa","volume":"27","author":"Delobeau","year":"2016","journal-title":"J\u00a0Dermatol Treat"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib66","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaad.2016.01.018","article-title":"Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases","volume":"74","author":"Faivre","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.014_bib67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.014_bib68","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.014_bib69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.12.014_bib71","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bjps.2016.05.029","article-title":"A\u00a0systematic review of the use of lasers for the treatment of hidradenitis suppurativa","volume":"69","author":"John","year":"2016","journal-title":"J\u00a0Plast Reconstr Aesthet Surg"},{"issue":"2","key":"10.1016\/j.det.2024.12.014_bib72","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamadermatol.2021.4741","article-title":"Patient impressions and outcomes after clinic-based hidradenitis suppurativa surgery","volume":"158","author":"Ravi","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib73","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/pde.14955","article-title":"Surgical deroofing in pediatric patients with hidradenitis suppurativa","volume":"39","author":"Leszczynska","year":"2022","journal-title":"Pediatr Dermatol"},{"issue":"3\u20134","key":"10.1016\/j.det.2024.12.014_bib74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/jocn.15088","article-title":"Distraction using virtual reality for children during intravenous injections in an emergency department: a randomised trial","volume":"29","author":"Chen","year":"2020","journal-title":"J\u00a0Clin Nurs"},{"issue":"3","key":"10.1016\/j.det.2024.12.014_bib75","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/wvn.12359","article-title":"The effect of distraction cards on reducing pain and anxiety during intramuscular injection in children","volume":"16","author":"Canbulat \u015eahiner","year":"2019","journal-title":"Worldviews Evid Based Nurs"},{"key":"10.1016\/j.det.2024.12.014_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2020.02.039","article-title":"Reducing pain and distress related to needle procedures in children with cancer: a clinical practice guideline","volume":"131","author":"Loeffen","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.det.2024.12.014_bib77","first-page":"CD005179","article-title":"Psychological interventions for needle-related procedural pain and distress in children and adolescents","volume":"10","author":"Birnie","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:31:09Z","timestamp":1751376669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0733863524001141"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.12.014","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hidradenitis Suppurativa in Children","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}